Edition:
United States

Biotec Pharmacon ASA (BIOTEC.OL)

BIOTEC.OL on Oslo Stock Exchange

11.20NOK
26 Aug 2016
Change (% chg)

kr-0.10 (-0.88%)
Prev Close
kr11.30
Open
kr11.25
Day's High
kr11.40
Day's Low
kr11.15
Volume
37,539
Avg. Vol
50,513
52-wk High
kr18.00
52-wk Low
kr10.00

BIOTEC.OL

Chart for BIOTEC.OL

About

Biotec Pharmacon ASA is a Norway-based biopharmaceutical company that develops, manufactures and markets immune modulating compounds for the human health sectors and marine enzymes used in molecular biology. The Company focuses on new solutions within wound care, cancer therapies and other immune related disease areas. It has a... (more)

Overall

Beta: -0.46
Market Cap(Mil.): kr492.18
Shares Outstanding(Mil.): 43.94
Dividend: --
Yield (%): --

Financials

  BIOTEC.OL Industry Sector
P/E (TTM): -- 36.93 36.63
EPS (TTM): -0.43 -- --
ROI: -20.81 14.69 14.12
ROE: -20.81 15.48 15.04

BRIEF-Biotec Pharmacon Q2 EBITDA loss widens to NOK 1.6 mln

* Q2 revenue 15.3 million Norwegian crowns ($1.86 million) versus 11.5 million crowns year ago

Aug 17 2016

BRIEF-Biotec Pharmacon files 510K application for US market

* Says will file 510K application for Woulgan for US market this week

Jun 30 2016

BRIEF-Biotec Pharmacon signs German distribution agreement for Woulgan

* Enters into distribution agreement for Woulgan with the German distributor Rogg Verbandstoffe GmbH

Jun 13 2016

BRIEF-Biotec cleared in arbitration matter

* Received the decision by the arbitration court related to the Company's nutrition business brought up by company Sana Pharma AS

Jun 13 2016

BRIEF-Biotec Pharmacon Q1 EBITDA widens to loss NOK 3.5 mln

* Q1 revenue 17.3 million Norwegian crowns ($2.11 million)versus 12.3 million crowns year ago

Apr 19 2016

BRIEF-Biotec Pharmacon Q1 EBITDA widens to loss NOK 3.5 mln

* Q1 revenue 17.3 million Norwegian crowns ($2.11 million)versus 12.3 million crowns year ago

Apr 19 2016

BRIEF-Biotec Pharmacon unit awarded funding from Horizon2020 programme

* ArcticZymes, a subsidiary of Biotec Pharmacon has received 460,000 euros ($523,388.00) over the next four years in a project funded by the European Framework Programme for Research and Innovation, Horizon 2020 Source text for Eikon:

Apr 01 2016

BRIEF-Biotec BetaGlucans has entered into supply agreement for delivery of M-Glucan

* Subsidiary Biotec BetaGlucans AS has entered into a supplier agreement with a new feed company for deliveries of its beta-glucan product M-Glucan for use in animal health

Mar 11 2016

BRIEF-Biotec Pharmacon receives notice of allowance for Woulgan gel in USA

March 3 Biotec Pharmacon ASA : * Has received notice of allowance for Woulgan gel in the US Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Mar 03 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Reuters Investment Profile
$20.00
Provider : Wright Reports
$75.00
Provider : Directors Deals Ltd.
$12.00
Provider : GlobalData
$300.00
Provider : GlobalData
$300.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.